NCT01759303

Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung

A Phase II Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Emerald Clinical Inc. · Industry
• Sex: All
• Age: 16 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the 4-month Progression-Free Survival (PFS), with demonstrated increase in tumor doubling time, of eligible subjects treated with pazopanib according to RECIST version 1.1 guidelines.

Conditions

• Osteosarcoma
• Metastatic Osteosarcoma

Interventions

Type	Name	Description
DRUG	pazopanib	For subjects \> 18 years of age and subjects 16-17 years of age with a BSA ≥ 1.6 Pazopanib 800mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity. For subjects 16-17 years of age with a BSA \< 1.6 m2, Pazopanib 600mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity.

Timeline

• Start date: 2013-04-01
• Primary completion: 2017-01-01
• Completion: 2017-05-01
• First posted: 2013-01-03
• Last updated: 2021-04-13

Locations

4 sites across 1 country: United States